ES2192205T3 - Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero. - Google Patents

Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero.

Info

Publication number
ES2192205T3
ES2192205T3 ES95932094T ES95932094T ES2192205T3 ES 2192205 T3 ES2192205 T3 ES 2192205T3 ES 95932094 T ES95932094 T ES 95932094T ES 95932094 T ES95932094 T ES 95932094T ES 2192205 T3 ES2192205 T3 ES 2192205T3
Authority
ES
Spain
Prior art keywords
activity
control
inflammation
hemooxigenasa
mammer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932094T
Other languages
English (en)
Inventor
Dean Willis
Adrian Richard Moore
Derek Albert Willoughby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Negma Lerads SA
Original Assignee
Negma Lerads SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4154382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2192205(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Negma Lerads SA filed Critical Negma Lerads SA
Application granted granted Critical
Publication of ES2192205T3 publication Critical patent/ES2192205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mirrors, Picture Frames, Photograph Stands, And Related Fastening Devices (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Rear-View Mirror Devices That Are Mounted On The Exterior Of The Vehicle (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE CONSIGUE CONTROLAR LA INFLAMACION MEDIANTE EL CONTROL DEL NIVEL Y/O ACTIVIDAD DE LA ENZIMA HEMO-OXIGENASA (HO). EL INDUCTOR HO ES ANTIINFLAMATORIO (DIBUJO 14) Y SE UTILIZA PARA TRATAR INFLAMACIONES COMO PUEDEN SER LAS ENFERMEDADES INFLAMATORIAS CRONICAS. EL INHIBIDOR HO FAVORECE LA INFLAMACION Y SE UTILIZA PARA TRATAR AFECCIONES DE INMUNOSUPRESION. DE FORMA ALTERNATIVA, O ADICIONAL, SE CONSIGUE EL CONTROL DE LA ACTIVIDAD DE LA HEMOOXIGENASA MEDIANTE EL CONTROL DE LOS NIVELES DE OXIDO NITRICO, YA QUE LOS NIVELES ELEVADOS FAVORECEN LA INFLAMACION.
ES95932094T 1994-09-22 1995-09-22 Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero. Expired - Lifetime ES2192205T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002132690A CA2132690A1 (en) 1994-09-22 1994-09-22 Control and modulation of inflammatory response in humans in need of such control and modulation

Publications (1)

Publication Number Publication Date
ES2192205T3 true ES2192205T3 (es) 2003-10-01

Family

ID=4154382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932094T Expired - Lifetime ES2192205T3 (es) 1994-09-22 1995-09-22 Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero.

Country Status (12)

Country Link
EP (1) EP0782441B1 (es)
JP (1) JPH10506388A (es)
CN (1) CN1213742C (es)
AT (1) ATE233551T1 (es)
AU (1) AU3528195A (es)
CA (1) CA2132690A1 (es)
DE (1) DE69529831T2 (es)
DK (1) DK0782441T3 (es)
ES (1) ES2192205T3 (es)
NZ (1) NZ292963A (es)
PT (1) PT782441E (es)
WO (1) WO1996009038A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
WO1999023097A1 (en) 1997-11-03 1999-05-14 Duke University Substituted porphyrins
ES2257858T3 (es) 1998-04-24 2006-08-01 Duke University Porfirinas sustituidas.
AR024523A1 (es) 1998-12-17 2002-10-16 Sangstat Medical Corp Metodo para aumentar la sobrevida de un injerto por modulacion de la actividad de hemo oxigenasa
ATE312103T1 (de) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
EP1439842A4 (en) 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
NZ534912A (en) 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
BRPI0616448A2 (pt) * 2005-09-30 2011-06-21 Ovation Pharmaceuticals Inc método de tratar e de profilaxia de pancreatite, método de induzir gene ho e método de tratamento ex vivo de pancreatite
CN102105146A (zh) 2008-05-23 2011-06-22 国立犹太保健医院 用于治疗与暴露于烷化物质有关的损伤的方法
DK2536285T3 (en) * 2010-02-18 2018-07-16 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
CN105727379A (zh) * 2016-02-25 2016-07-06 顾宇春 血红素加氧酶药物洗脱支架
CN110585215B (zh) * 2019-09-19 2023-06-02 中山大学 氯化血红素及其复合物在医药中的新应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
WO1992018112A1 (en) * 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
WO1993007114A1 (en) * 1991-09-24 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
EP0673236A4 (en) * 1992-12-10 1999-07-07 Hemogen Inc METHOD FOR STIMULATING THE PRODUCTION OF HEM OXYGENASE USING VITAMIN B12.

Also Published As

Publication number Publication date
EP0782441B1 (en) 2003-03-05
CN1213742C (zh) 2005-08-10
WO1996009038A2 (en) 1996-03-28
CN1166785A (zh) 1997-12-03
DE69529831T2 (de) 2003-12-24
JPH10506388A (ja) 1998-06-23
PT782441E (pt) 2003-07-31
CA2132690A1 (en) 1996-03-23
EP0782441A1 (en) 1997-07-09
WO1996009038A3 (en) 1996-06-13
ATE233551T1 (de) 2003-03-15
AU3528195A (en) 1996-04-09
NZ292963A (en) 2001-06-29
DE69529831D1 (de) 2003-04-10
DK0782441T3 (da) 2003-06-30

Similar Documents

Publication Publication Date Title
ES2192205T3 (es) Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero.
DE3584172D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstenone und ihre anwendung als 5-alpha-reduktase-inhibitoren.
MX9308199A (es) Inhibidores de enzima.
DE19975031I2 (de) Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.
DE69738693D1 (de) On wunden- und brandheilung
IT8123988A0 (it) Impiego della combinazione di un inibitore della aromatasi con un antiandrogeno per la profilassi ela terapia dell'iperplasia della prostata.
DK0767654T3 (da) Antiseptisk tandplejemiddel
FI940033A7 (fi) Terpolymeerit, jotka pohjautuvat alfa,beta-tyydyttymättömiin dikarboksyylihappoanhydrideihin, alfa,beta-tyydyttymättömiin yhdisteisiin ja alempien, tyydyttymättömien alkoholien polyoksialkyleenieettereihin
DE69030716D1 (de) Ausgangsverstärkerstufe mit Leistungsaufnahmeverringerungseigenschaften
ES2121779T3 (es) Utilizacion de espiperona como agente inmunosupresor y antiinflamatorio.
DK1032414T3 (da) Kombination af inhibitor for angiotensinomdannende enzym med et diuretikum til behandling af forstyrrelser i mikrokredsløbet
DE69609864D1 (de) Steroidnitritesterderivate und ihre verwendung als entzündungshemmende medikamente
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
SV1994000076A (es) Derivados de acido n-acetil neuraminico cristalino y su preparacion ref. 1123a/sv
ES2094267T3 (es) Utilizacion de micelio de hongos como agente auxiliar para suelos.
MY106885A (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
FR2569569B1 (fr) Exerciseur destine notamment au travail du grand ecart.
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ES2161293T3 (es) Derivados de enol acilados como profarmacos de inhibidores de la elastasa.
WO1998047494A3 (en) Novel use of matrix metalloproteinase inhibitors
DK0673646T3 (da) Anvendelse af deoxyspergualin til fremstilling af et lægemiddel til behandling af inflammatorisk-hyperreaktive sygdomme
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
IT8421358A0 (it) Derivato della ranitidina utile nel trattamento dell'ulcera.
IT8819447A0 (it) Composizione di composti che migliorano l'attivita' analgesica, antipiretica e antinfiammatoria.
FR2690344B1 (fr) Compositions therapeutiques a dosage topique dans le traitement effectif de la psoriasis.